We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Three-Dimensional Model Reveals How Breast Tissue Grows

By LabMedica International staff writers
Posted on 15 Sep 2011
Investigators have developed an innovative three-dimensional (3D) model that allows them to visualize how breast tissue grows in its earliest stages, giving them the clearest view ever at the very beginnings of breast cancer.

This research was described in the August 1, 2011, issue of the journal Genes & Development. Results from this study and ongoing research at the University of Virginia (UVA; Charlottesville, USA) Health System could lead to the development of more effective drugs and even the advancement of personalized medications to treat breast cancer.

The new model represents a major scientific milestone--it is the first time scientists have been able to replicate effectively and accurately the early growth of human breast tissue outside of the body. More...
“These findings have important implications for the study and understanding of breast cancer,” said Deborah Lannigan, PhD, associate professor in the UVA School of Medicine’s department of microbiology, immunology, and cancer biology. “Like never before, researchers around the world now have a means of understanding how breast cancer begins and progresses.”

Nearly 90% of breast cancers begin in the breast’s ducts, so knowing how they form is crucial to developing improved therapies. A network of breast ducts resembles a tree branch--each arm of the duct is elongated and cylindrical and consists of an outer layer of cells (basal) and an inner layer of cells (luminal). Some breast cancers arise from basal cells and some grow from luminal cells. The outer, basal layer of cells acts as a barrier that is thought to help keep early cancerous cells from escaping out of the ducts and spreading into the rest of the body.

UVA researchers employed their model to determine what mechanisms in the body control the development of breast ducts, particularly the outer basal cells. They discovered that a signal produced by the body, called epidermal growth factor (EGF), tells the ducts how many basal cells to produce. This finding is a significant step in determining how basal tumors might form, and how normal basal cells might block the metastasis of cancers.

Using the new model, UVA researchers also found that human breast tissue is much more sensitive to growth factors than that of mice. “These differences might explain why some drugs are less effective in patients than would have been predicted from animal studies,” suggested Ian Macara, PhD, professor of microbiology and a coinvestigator on the study.

The new model was developed by a unique multidisciplinary team of UVA Health System researchers, including the team of cell biologists Drs. Lannigan and Macara, along with breast surgeon David Brenin, MD, and pathologist Chris Moskaluk, MD, PhD. All combined their areas of expertise to design an innovative and better way of studying breast cancer at its earliest stages.

Related Links:
University of Virginia



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.